Ian Anthony James Lorimer
Affiliations: | Biochemistry, Microbiology and Immunology | University of Ottawa, Ottawa, ON, Canada |
Area:
Biochemistry, Cell Biology, OncologyWebsite:
http://www.ohri.ca/profile/ilorimerGoogle:
"Ian Anthony James Lorimer"Bio:
Parents
Sign in to add mentorBishnu D. Sanwal | grad student | 1989 | Western University (Chemistry Tree) | |
(Regulation of cAMP-dependent protein kinases during skeletal myogenesis.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Lorimer IA. (2019) Aberrant Rac pathway signalling in glioblastoma. Small Gtpases. 1-15 |
Jacques FH, Nicholas G, Lorimer I, et al. (2019) Avelumab in newly diagnosed glioblastoma multiforme: The SEJ study. Journal of Clinical Oncology. 37 |
Lorimer I, Lavictoire S, Jomaa D, et al. (2019) Csig-12. Prex1 Links Aberrant Pi 3-Kinase Pathway Signaling To Maintenance Of The Neural Stem Cell-Like Phenotype Of Glioblastoma Cells Neuro-Oncology. 21 |
Kumar R, Lorimer I. (2018) Csig-06. The Molecular Subtype Of Primary Glioblastoma Cells Correlates With Response To Therapeutic Agents That Induce Apoptosis Or Senescence Neuro-Oncology. 20 |
Gont A, Daneshmand M, Woulfe J, et al. (2016) PREX1 integrates G protein-coupled receptor and phosphoinositide 3-kinase signaling to promote glioblastoma invasion. Oncotarget |
Restall IJ, Parolin DA, Daneshmand M, et al. (2015) PKCι DEPLETION INITIATES MITOTIC SLIPPAGE-INDUCED SENESCENCE IN GLIOBLASTOMA. Cell Cycle (Georgetown, Tex.). 0 |
Jahani-Asl A, Yin H, Soleimani V, et al. (2015) CSIG-06EGFRvIII REQUIRES OSMR AS A CO-RECEPTOR TO DRIVE GLIOBLASTOMA PATHOGENESIS Neuro-Oncology. 17: v67.2-v67 |
Gont A, Hanson JE, Lavictoire SJ, et al. (2014) Inhibition of glioblastoma malignancy by Lgl1. Oncotarget. 5: 11541-51 |
Karapetis CS, Jonker D, Daneshmand M, et al. (2014) PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 744-53 |
Goss GD, O'Callaghan C, Lorimer I, et al. (2013) Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3320-6 |